

Review

Open Access

Control of human trophoblast function

Laura Lunghi¹, Maria E Ferretti¹, Silvia Medici¹, Carla Biondi¹ and Fortunato Vesce^{*2}

Address: ¹Department of Biology, Section of General Physiology, University of Ferrara, 44100 Ferrara, Italy and ²Department of Biomedical Sciences and Advanced Therapy, Section of Obstetrics and Gynaecology, University of Ferrara, 44100 Ferrara, Italy

Email: Laura Lunghi - laura.lunghi@unife.it; Maria E Ferretti - frmnr@unife.it; Silvia Medici - mdcslv@unife.it; Carla Biondi - clm@unife.it; Fortunato Vesce* - ves@unife.it

* Corresponding author

Published: 8 February 2007

Received: 2 October 2006

Reproductive Biology and Endocrinology 2007, **5**:6 doi:10.1186/1477-7827-5-6

Accepted: 8 February 2007

This article is available from: <http://www.rbej.com/content/5/1/6>

© 2007 Lunghi et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The trophoblast, i.e. the peripheral part of the human conceptus, exerts a crucial role in implantation and placentation. Both processes properly occur as a consequence of an intimate dialogue between fetal and maternal tissues, fulfilled by membrane ligands and receptors, as well as by hormone and local factor release. During blastocyst implantation, generation of distinct trophoblast cell types begins, namely the villous and the extravillous trophoblast, the former of which is devoted to fetal-maternal exchanges and the latter binds the placental body to the uterine wall. Physiological placentation is characterized by the invasion of the uterine spiral arteries by extravillous trophoblast cells arising from anchoring villi. Due to this invasion, the arterial structure is replaced by amorphous fibrinoid material and endovascular trophoblastic cells. This transformation establishes a low-resistance, high-capacity perfusion system from the radial arteries to the intervillous space, in which the villous tree is embedded. The physiology of pregnancy depends upon the orderly progress of structural and functional changes of villous and extravillous trophoblast, whereas a derangement of such processes can lead to different types of complications of varying degrees of gravity, including possible pregnancy loss and maternal life-threatening diseases. In this review we describe the mechanisms which regulate trophoblast differentiation, proliferation, migration and invasiveness, and the alterations in these mechanisms which lead to pathological conditions. Furthermore, based on the growing evidence that proper inflammatory changes and oxidative balance are needed for successful gestation, we explain the mechanisms by which agents able to influence such processes may be useful in the prevention and treatment of pregnancy disorders.

Introduction

Trophoblast is an embryonic tissue which exerts a crucial role during implantation and placentation. Both processes can only take place through a significant change in the uterine wall in response to different modulatory molecules, among which steroid and peptide hormones, as well as local factors including prostanoids. This transfor-

mation, aimed at creating a favourable environment for receiving the blastocyst, and permitting embryo-fetal development, is represented by a complex series of events termed decidualization. Implantation consists of the blastocyst penetrating the luminal epithelium, crossing the basal lamina and, finally, embedding itself in the stroma. During implantation a syncytiotrophoblast (ST) is

formed, which begins to invade the maternal tissue. Afterwards, vascularization of the trophoblast occurs in order to establish and maintain a fetoplacental vasculature. Simultaneously, maternal vascular remodeling takes place so as to generate a uteroplacental circulation. For successful placentation to occur, a highly orchestrated control of vasculogenesis, angiogenesis, and trophoblast functions is required. This is operated by a large number of heterogeneous factors which act by both autocrine and paracrine mechanisms.

Here we review the control of trophoblast function, highlighting the aspects which may improve management of pregnancy complications.

Decidualization

In order for implantation to occur, endometrium has to be changed into decidua. This process consists in modifying endometrial stromal cells, uterine glands and vessels, as well as the population of uterine immune cells. In humans, unlike other species [1], decidualization is independent of the blastocyst's presence in the uterine cavity and begins in the late secretory phase of the menstrual cycle. It is evoked by progesterone, as well as by regulatory agents able to enhance cyclic AMP (cAMP) levels [2,3]. Decidualization continues in pregnancy, and it is thought to regulate subsequent trophoblast invasion and placenta formation by altering the expression of regulatory factors such as metalloproteinases, cytokines, surface integrins, and major histocompatibility complex molecules. The trophoblast, in turn, releases paracrine signals which modulate decidual stromal cell gene expression [4]. These cells become round and show ultrastructural similarities with myofibroblasts and epithelial cells [5]. Moreover, they release several factors including prolactin, relaxin, renin, insulin-like growth factor binding protein-1 (IGFBP-1) [1,3] and specific extracellular matrix (ECM) proteins such as laminin and fibronectin [6]. *In vitro* studies have demonstrated that this event is correlated with changes in steroid hormone receptor expression and steroid metabolism, remodeling of the ECM and cytoskeleton, altered expression of enzymes, growth factors and cytokines, and induction of apoptosis modulators and specific transcription factors [7]. Elongation of the spiral arteries occurs through an endometrium-specific angiogenesis, characterized by proliferation of both endothelial and smooth muscle cells, with preservation of the integral structure of the vessel. In the uterine wall, several leukocyte types, such as T lymphocytes, a few B lymphocytes, macrophages, and natural killer (NK) cells, are present. However, after ovulation, a dramatic increase in NK cells is observed. Uterine NK cells (uNK) are phenotypically and functionally different from circulating ones. Indeed, they have not cytolytic activity [8], and express integrins which allow their migration and invasion of the decidual-

izing endometrium [6]. It has been suggested that the unique environment resulting from the transformation of endometrium to decidua plays a crucial role in uNK cell specificity acquisition [6,9]. Since decidual NK cells decrease in number in the second half of pregnancy and disappear at delivery, it has been hypothesized that their main role is confined to early pregnancy, when they modulate implantation and placentation interacting with both decidual stromal cells and trophoblast [6,9]. Interestingly, it has been shown that uNK cell recruitment is a hormonally-controlled maternal function and is independent of the presence of the implanting embryo [10]. NK cell survival seems to be dependent upon the presence of progesterone, whose action, however, is presumably not direct, but mediated by decidual stromal cells which express hormone receptors [11]. In contrast, it has recently been shown that glucorticoids are able to decrease the number of decidual NK cells [12].

Decidualization is also characterized by a decrease in Th1 and an increase in Th2 lymphocytes, an effect which is evoked by progesterone and cytokines. It has been proposed that Th2 cytokines protect fetus and trophoblasts inhibiting NK cell cytotoxicity and proliferation, shifting NK cell cytokine production toward a Th2 phenotype, as well as suppressing cytotoxic T cells activation [12-14].

Blastocyst implantation

An intimate cross-talk between the embryo and the uterus is needed for blastocyst implantation [4,15]. This process, which consists of an interaction between trophoblast cells and endometrium, can only take place in a restricted period of time, termed "window of receptivity". It is initially dependent upon the presence of estrogen and progesterone, although further morphological and biochemical changes are evoked within the uterine wall by signals from the embryo and invading trophoblast. The "window of receptivity" in humans is presumed to span days 20-24 of the menstrual cycle [1]. Indeed, out of this period the epithelium apical surface is covered by a thick glycocalyx, mainly composed of mucin, and in particular MUC1, a transmembrane glycoprotein characterized by an extended extracellular domain which prevents blastocyst attachment [16]. Blastocyst implantation is also impaired by the large number of desmosomes which exist along lateral epithelial cell surfaces [17]. In some species the "window of receptivity" is characterized by down-regulation of MUC1, but this condition has not been observed in humans. Some researchers have suggested that MUC1 may actually promote human blastocyst attachment to the uterine wall [18], whereas others demonstrated a loss of this mucin at the site of blastocyst interaction [19] thanks to uterine proteases, activated by factors released from the blastocyst itself [16].

Blastocyst attachment to the uterine wall depends upon the interaction between adhesion molecules such as selectins, integrins, and trophinins [17], expressed on both trophoblast cells and uterine epithelium. This interaction is mediated, in most cases, by bridging ligands including, at least in the sheep, osteopontin and galectin-15, which are released in the uterine cavity by endometrial glands [20]. Invasion is favoured by the simultaneous decrease of desmosome density and basal membrane digestion, finally leading to nidation in the decidual stroma [17].

A key role in the control of human blastocyst implantation is exerted by endometrial chemokines and cytokines. Chemokines are thought to be responsible for the promotion of leukocyte migration to the decidua, where they cause a sort of inflammatory state, a process which appears to derive from several sources. First, decidualization is characterized by NK cells interaction with the non-polymorphic HLA class I antigens expressed by invading trophoblasts [21]. Furthermore, signalling agents secreted by seminal vesicles and prostate gland interact with epithelial cells in the cervix and uterus, recruiting and activating macrophages, granulocytes and dendritic cells. They are provided with immune-regulatory and tissue remodeling roles that improve endometrial receptivity to the implanting embryo. Tumor growth factor β (TGF- β) and prostaglandins (PGs) present in seminal fluid contribute to enhance cytokine production and vascular permeability, that appear to be essential for implantation, due to their effects favouring blastocyst attraction and attachment to the endometrium [13]. Moreover chemokines, interacting with G protein-coupled receptors, induce a structural change in integrins which favours adhesion of the blastocyst to the decidualized endometrium [22]. NO favours blastocyst implantation in both animals and humans, modulating PG release, ovarian steroidogenesis, uterine cell proliferation, glandular secretion and blood flow, as well as mediating sex steroid and growth factor actions [15]. Since normal pregnancy is a physiological process, in our opinion it should not be defined as a 'controlled state of inflammation' [23]. However, at an early stage at the implantation site, as well as later systemically, it is regulated by the same cytokines whose derangement can trigger the inflammatory pathway, leading to various types of early and late gestational diseases. Under such profile, the above mentioned 'Th1/Th2' shift hypothesis, that dominated reproductive immunology for many years, should be more simply interpreted as the expression of the modulation of the cytokines that regulate the vascular processes of placentation, rather than a specific mechanism to avoid fetal T-cell rejection.

Trophoblast differentiation and function

The formation of floating and anchoring villi begins immediately after nidation. Three stages are recognized in the development of the villi, namely primary, secondary and tertiary villi, the last being characterized by a de-novo formation of capillaries from mesenchymal precursors and thus devoted to feto-maternal exchanges. Villous tree expansion occurs throughout pregnancy [24].

The specialized villous cell types, i.e. ST and extravillous trophoblast (EVT) cells, originate from cytotrophoblast (CT) stem cells. During blastocyst implantation, CT cells fuse to form an external layer of non-proliferative multinucleated ST which then grows thanks to the steady incorporation of new CT cells. ST exerts a crucial role in feto-maternal exchanges and possesses endocrine activity, releasing hormones involved in the homeostasis of pregnancy such as chorionic gonadotrophin (CG) and placental lactogen (PL). Around day 14 after implantation, CT cells break through the ST layer giving rise to EVT cells, which begin to invade the uterine stroma as trophoblastic cell columns. From the tips of the columns, a subpopulation of these motile and invasive cells moves laterally, to form the trophoblastic shell, and longitudinally to invade deeply the decidua and the deeper portion of the myometrium, where these cells evoke profound changes within the uterine vessels [25].

Factors involved in the control of CT differentiation

Differentiation of CT to ST or EVT cells is precisely controlled by different agents such as transcription factors, specific genes, hormones, growth factors, cytokines and O_2 levels. The glial cell missing factor 1 (GCM1), together with the AP-2 and Sp transcription factor families, stimulate syncytial fusion, whereas Hash-2 inhibits this process by reducing CYP19/aromatase gene transcription [26]. Hash-2 and Id-2 maintain CT proliferation, and their downregulation is observed in differentiated cells [27,28]. The expression of some of the above mentioned transcription factors is influenced by O_2 levels and cAMP.

A relatively low oxygen environment characterizes blastocyst implantation, placentation and early embryonic development up to the 10th week of gestation [29]. Accordingly, in the first trimester, the villous trophoblastic layer is twice the thickness it becomes in the second. Moreover, the intervillous circulation is established peripherally at around the 9th week, and it enlarges to encompass the whole placenta only after the 12th week. This could be due to the presence of trophoblast cell plugs which occlude the tips of the uteroplacental arteries [30], or to incomplete spiral artery remodeling [31]. Low O_2 levels stimulate CT proliferation and inhibit EVT and ST differentiation. Hypoxia acts by modifying gene expres-

sion or mRNA stability [32]. For instance it stimulates the expression of both the hypoxia inducible factor-1 (HIF-1), which maintains CT proliferation, and HIF-2, thus preventing differentiation. Moreover it has been reported that, in first-trimester trophoblast, HIF-1 expression parallels that of TGF- β 3, an inhibitor of early trophoblast differentiation which impairs its acquisition of the invasive phenotype [31,33]. In line with this last report, it has been observed that invading CT downregulates the expression of both HIF-1 and TGF- β 3 genes [33,34]. cAMP also seems to be involved in trophoblast differentiation and it has been shown to influence ST formation. It enhances AP-2 and Sp functionality, promotes the expression of the syncytin gene, a highly fusogenic membrane protein localized at the CT-ST interface, and mediates the syncytialization evoked by CG [35]. Among growth factors, the vascular endothelial growth factor (VEGF), whose expression has been demonstrated in decidual cells, CT and EVT [36-38], stimulates CT differentiation to both ST and endovascular EVT, and its effect is inhibited by soluble fms-like tyrosine kinase-1 (sFlt-1), which acts by binding VEGF [39].

TGF- β , instead, inhibits differentiation along the invasive pathway helped by endoglin, a component of TGF- β receptor complex [40], while tumor necrosis factor (TNF)- α reduces syncytialization [41]. The involvement of canonical Wnt signaling and of marinobufagenin, the endogenous sodium pump inhibitor, has recently been reported in the acquirement of the invasive phenotype [42,43]. An alteration of trophoblast differentiation may result in pregnancy diseases, such as preeclampsia. For instance a persistent hypoxia, together with an increase of HIF-1 and TNF- α as [44] well as a decrease of syncytin expression [45], induces a decrement of syncytialization and consequently an enhancement of trophoblast apoptosis, an event notoriously involved in preeclampsia pathogenesis. A schematic representation of the above described control of trophoblast differentiation is reported in Fig. 1.

Extravillous trophoblast function

EVT cells originating from the trophoblastic shell first enter the decidua and subsequently the myometrial stroma [3] as interstitial trophoblast. This encircles and destroys the smooth muscle cells of spiral artery media which is replaced by amorphous fibrinoid material. Subsequently, EVT expressing an endothelial phenotype invade the lumen of the arteries [46] to replace the endothelium of the vessels (Fig. 2).

Invasion of endometrial vessels by endovascular EVT is evident from 8 weeks onward, whereas myometrial artery invasion begins around the 14th week. This process mainly involves the vessels in the center of the placental bed, but

also to a lesser extent the peripheral vasculature [47]. The expression of both angiopoietins and their receptor (Tie-2) has been observed during early placentation, suggesting an involvement of these regulatory agents in vascular remodeling. Moreover, the demonstration that Tie-2 is expressed on trophoblast suggests that angiopoietins may regulate its functions. For instance, it has been demonstrated that angiopoietins stimulate proliferation and migration of cultured cytotrophoblast and EVT cells, respectively [36]. Since the guinea pig interstitial trophoblast expresses NO synthases [48], a role for NO in dilating and remodeling uterine vessels has been hypothesized. However, human invasive trophoblast does not express NO synthesizing enzymes [49], and therefore it should not be able to release this vasoactive molecule. Another putative vasodilator is carbon monoxide, produced by hemoxygenase, whose expression has been demonstrated in all EVT cells [50]. Furthermore, molecules able to interact with each other have been identified in both NK and EVT cells [9]. In EVT cells MHC class I molecules are expressed, in particular HLA-C, E and G that are all good ligands for several members of the killer immunoglobulin receptor (KIR) family, present on NK cells. Such interaction modifies the NK cell cytokine repertoire and regulates adhesion molecules as well as matrix metalloproteinase (MMP) functionality [51]. Interstitial EVT cells move to the inner myometrium, where they fuse to become placental bed giant cells (GC) [52]. Since these multinuclear cells lose their ability to migrate and invade, their formation is likely to represent a mechanism which prevents deeper penetration into the uterine wall.

Invading EVT cells up-regulate the expression of proteins which favour uterine wall invasion, including MMPs, α 5 β 1 and α 1 β 1 integrins, VE-cadherin, and the trophoblast specific HLA class 1 molecule (HLA-G) which probably exerts a role in preventing fetal rejection. Conversely, these cells down-regulate the expression of adhesion molecules, such as α 6 β 4 integrin or E-cadherin, unqualified for the invasion process, or of regulatory factors which inhibit cell invasiveness [53].

In addition to CT differentiation, O₂ levels also influence EVT cell function. An inhibitory effect of hypoxia on EVT cell invasiveness has been reported [31,33,54], which is thought to be due to a modification of the integrin expression pattern which is, in turn, influenced by components of the ECM [54]. However, under different experimental conditions, an enhancement of trophoblast cell line invasiveness has also been observed [55]. This effect has been related to an enhanced expression of urokinase-type plasminogen activator (uPAR), an event which then results in the activation of plasmin and latent MMPs [55]. According to Genbacev *et al* [31] hypoxia does not inhibit




Figure 1

Schematic representation of cytotrophoblast (CT) differentiation to syncytiotrophoblast (ST) or extravillous trophoblast (EVT), together with some of the key factors involved in the control of these events. The box on the left lists factors stimulating CT proliferation, thus inhibiting differentiation. Boxes on the right list factors stimulating or inhibiting ST or EVT cell formation.

cytotrophoblast differentiation/invasion before the 7th week of gestation.

Modulation of EVT function is a complex phenomenon which depends on a growing number of factors [13,56], beside those above described. However, the majority of available data were obtained from *in vitro* experiments, and contrasting responses may derive from different experimental conditions [57,58]. It is therefore impossible at present to describe the *in vivo* picture. Some of the key regulators of EVT functions are listed in Table 1.

The influence of the oxidative balance on trophoblast functions and embryo development

The oxidative balance in the gestational sac, besides influencing CT differentiation and EVT cell function, affects embryo survival and development. It is known that hypoxia in embryonic stem cells evokes HIF-1 gene expression which, in turn, activates multiple genes

involved in both proliferation/differentiation and in cellular adaptive responses to low O₂ availability [74].

The hypoxic milieu, in which the conceptus develops in early pregnancy, may serve to protect fetal tissues and developmental processes against the deleterious effects of the reactive oxygen species (ROS), during critical phases of embryogenesis and organogenesis. This protection is potentiated by the existence of internal and external antioxidant defense mechanisms. The former mainly comprise antioxidant enzymes such as superoxide dismutase, glutathione peroxidase and gamma-glutamylcysteine synthase. Transcripts encoding for these enzymes have been demonstrated in the oocyte, embryo and oviduct, and their expression seems essential to embryo acquisition of the propensity to develop. External defense mechanisms are represented by non-enzymatic antioxidants such as hypotaurine, taurine and ascorbic acid which are found in follicular and tubal fluids [75]. On the other hand, it has




Figure 2
Maternal spiral artery remodeling through the combined action of interstitial and endovascular extravillous trophoblast cells.

been established that human trophoblast cells, exposed to ROS or other cytotoxicants, overexpress the metal-binding protein metallothionein, which exerts a protective role by both direct and indirect mechanisms. In fact this protein is thought to bind and hence neutralize these toxicants, simultaneously releasing normally bound zinc, which possesses cytoprotective actions [76]. A schematic representation of defence mechanisms against ROS is reported in Fig. 3.

O₂ tension increases sharply at the end of the first trimester, when an enhancement of oxidative stress markers as well as of mRNAs for antioxidant enzymes occurs in trophoblast cells [77]. Such enzyme expression could be induced by NAD(P)H oxidases [78], stimulated by hypoxia itself, which leads to intracellular superoxide anion production. This subsequently upregulates the expression of antioxidant enzymes, possibly contributing to modulation of EVT function. Indeed, it has been dem-

onstrated that superoxide evokes the expression of HIF-1 and other genes related to vascular and matrix remodeling, as well as to cell apoptosis [78]. On the other hand, it is believed that a premature and widespread onset of antioxidant defense in the placenta, before the development of antioxidant defense in the placenta, is correlated to oxidative trophoblast damage and could represent a cause of early pregnancy loss [30].

The demonstration that physiological concentrations of ROS exert beneficial effects has led to the formulation of the "free radical theory of development". According to this theory, time course and pattern formation in developing organisms may be influenced by differential O₂ supplies and/or gradients in the intracellular redox state [79]. Indeed, it is known that low ROS concentrations stimulate cell proliferation as well as gene expression, and it has been suggested that ROS favourable actions may be related to their control of the local inflammatory reaction.

Table 1: some of the key factors regulating EVT cell functions

Factors	Source	Effect			Ref.
		Proliferation	Migration	Invasiveness	
Adhesion molecules	Trophoblast		↑↓	↑↓	53
Angiopoietins	Decidua, trophoblast		↑		36
Colony Stimulating Factor-I	Placenta, decidua	↑			59
Decorin	Decidua	↓	↓	↓	60
Epidermal Growth Factor	Decidua, trophoblast	↑		↑	61
Endothelin	Placental blood vessels, CT, ST, EVT		↑		62
Hepatocyte Growth Factor	Decidua, trophoblast		↑	↑	63
Insulin-like Growth Factor II	Trophoblast		↑	↑	64,65
Insulin-like Growth Factor Binding Protein-I	Decidua		↑	↑	64,65
Melanoma Cell Adhesion Molecule	Uterine smooth muscle cells		↓		66
Metalloproteinases	Trophoblast			↑	67
Nodal	Placenta	↓			68
Hypoxia				↑↓	54,55
Urokinase-type Plasminogen Activator	Trophoblast		↑	↑	69
Prostaglandin E₂	Decidua, trophoblast		↑		57
		↓	↓		58
8-iso-PGF_{2α}	Decidua			↓	70
Placental Growth Factor	Trophoblast	↑			71
TGF-β	Decidua, trophoblast, uNK cells	↓	↓	↓	61,64
TNF-α	Decidua, uNK cells, decidual macrophages		↓		72
VEGF	Decidua, trophoblast	↑			73

Recently, it has been evinced that physiological levels of ROS induce the expression of several cellular transcriptional factors, through the activation of multiple signal transduction pathways [80]. In contrast, high ROS levels are notoriously detrimental for cell survival and functions. *In vitro* investigations showed that the increased O₂ requirement by developing embryos enhances the rate of ROS production, thus representing a potential teratological threat to fetal tissues, as shown in the mouse model [81]. Moreover, injury caused by oxidative stress may be responsible for developmental retardation and arrest of mammalian preimplantation embryos. As for the mechanism responsible for this, it has been hypothesized that high ROS formation may initiate and propagate an inflammatory process, resulting in placental tissue apoptosis [82].

The role and modulation of the oxidative balance in pregnancy have recently been reviewed by Biondi *et al* [83].

Pathologic pregnancy

Perturbation of trophoblast functions may result in a range of adverse pregnancy outcomes such as malformation, fetal growth retardation, spontaneous abortion and stillbirth. For instance, a limited trophoblast invasion of maternal vessels has been correlated to both preeclampsia and fetal growth restriction, whereas an excessive trophoblast invasion is associated with invasive mole, placenta accreta and choriocarcinoma.

However, in spite of the the quantity of literature regarding the physiopathology of trophoblastic functions, the mechanisms leading to a successful pregnancy are far from fully understood. A modern approach to the matter is represented by the attempt to investigate the behaviour of the regulatory factors which are known to carry a high risk of spontaneous abortion in pregnancies, such as those complicated by fetal aneuploidy. Results obtained in this field demonstrate that chromosomal alterations in the embryo are correlated with anomalous amniotic and maternal plasma levels of growth factors and proinflammatory cytokines [84,85] which may impair trophoblast function. This concept is supported by the demonstration that trisomy 21 is associated with various defects in CT differentiation represented by down-regulation of adhesion molecules such as integrin α1 and, possibly as a compensatory mechanism, upregulation of MMP-9. These alterations may be responsible for the increase in CT apoptosis at the maternal-fetal interface [86].

Preeclampsia, a multifactorial syndrome thought to be caused by a combination of genetic, environmental, immunological and nutritional factors affects approximately 2–3% of all pregnant women and is a major cause of maternal and fetal morbidity and mortality. It is generally diagnosed in the third trimester and it is frequently, though not necessarily, responsible for pregnancy-induced hypertension and proteinuria. The pathological basis behind the clinical symptoms is represented by gen-




Figure 3

Antioxidant mechanisms which protect the embryo against ROS excessive formation. Superoxide dismutase (SOD), glutathione peroxidase (GPX) and gamma-glutamylcysteine synthase (GCS) transcripts have been identified in the oocyte, embryo and oviduct. The non-enzymatic antioxidants hypotaurine, taurine and ascorbic acid have been found in follicular and tubal fluids. Metallothionein is synthesized by trophoblast cells, and acts by neutralizing ROS and releasing the cell survival factor Zn^{2+} .

eralized vasoconstriction, increased vascular reactivity, parenchymal hypoperfusion, excessive edema, and platelet activation triggering the coagulation cascade [87].

In normal pregnancy, as described above, EVT cells transform the spiral arteries into low-resistance vessels. In preeclampsia, however, spiral artery remodeling is defective and the utero-placental circulation remains in a state of high resistance (Fig. 4). It has been hypothesized that poor placental perfusion *per se* is an insufficient prerequisite for preeclampsia; as a matter of fact, this pathologic condition appears only when altered placentation occurs together with maternal constitutional factors [69]. Both the mother and fetus contribute to preeclampsia, the fetal contribution being affected by paternal genes. Indeed, Hiby *et al* [88] recently indicated the following factors cor-

related to preeclampsia: HLA-C, on fetal trophoblast cells and KIRs, on maternal decidual NK cells. Both of these factors are characterized by an extensive polymorphism of immunological importance in this condition. In particular they suggest that mothers lacking most or all activating KIR are at a greatly increased risk of preeclampsia when the fetus possesses HLA-C belonging to the HLA-C2 group. In preeclampsia the dialogue between EVT and NK cells necessary for a correct spiral artery remodeling during early pregnancy cannot take place.

Several other factors have been implicated in the poor remodeling of spiral arteries, such as a defect in EVT cell differentiation toward the invasive phenotype, an increase in apoptosis, an imbalanced control of migratory and invasive EVT functions, and the inability of cells to adopt




Figure 4

Spiral artery remodeling in normal and abnormal placentation. During normal placentation, EVT cells invade uterine wall and maternal spiral arteries replacing smooth muscle with fibrinoid material and part of vessel endothelium, thus evoking artery dilatation. Decidual immune cells, like macrophages and NK cells, facilitate deep invasion of EVT cells up to myometrial portions of spiral arteries. A limited EVT cell invasion, in abnormal placentation, impairs the formation of the high-capacity, low-resistance feto-maternal circulation needed for an adequate oxygen and nutrient supply for the growing fetus. For cell type description, see figure 2.

an endovascular phenotype [69,89,90]. In contrast, Broens *et al* [3] proposed the scarce myometrial artery transformation may be due to a deficient myometrial decidualization, rather than to defective trophoblast invasion. Nevertheless, it has been reported that in preeclampsia CT cells fail to down-regulate $\alpha 6\beta 4$, to up-regulate $\alpha 1\beta 1$ integrins and to enhance MMP and HLA-G expression, whereas they maintain an elevated production of E-cadherin and of the anti-invasive factor, TGF- β [52]. Moreover, Redline *et al* [91] demonstrated that this pathological condition is associated with an excess of proliferative immature intermediate trophoblast cells, probably due to dysregulation of some cytokine and growth factor secretion. Indeed altered levels of several cytokines, produced at the maternal-fetal interface and involved in the physiological control of EVT cell proliferation, differenti-

ation and function, have been found in the blood of preeclamptic women [87]. It has also been hypothesized that enhancement of IL-2 production, due to the reduced placental HLA-G expression, is responsible for the scarce invasiveness of preeclamptic trophoblast [92], and that deficiency of IL-10 may contribute to enhanced inflammatory responses elicited by TNF- α and interferon- γ towards the trophoblast [50]. The enhanced pro-inflammatory/anti-inflammatory cytokine ratio is mainly due to the shift to a Th1-predominant state, clearly demonstrated in preeclampsia, and probably associated to an excessive production of inflammatory agents, among which IL-12 [14]. Abnormalities in TGF- $\beta 3$ expression are also associated with preeclampsia and it has been demonstrated that down-regulation of this growth factor restores the invasive capability of preeclamptic trophoblast cells [34]. Caniggia

et al [33] hypothesized that an up-regulation of both TGF- β 3 and HIF-1 expression, secondary to a failure in the change in O₂ tension during early placentation or to a defect in the ability of trophoblast cells to respond to this change, could arrest trophoblast differentiation along the invasive pathway. Alterations in the invasion-regulating system, uPA/uPAR/PAI, may also contribute to the development of preeclampsia since reduced levels of uPA and increased concentrations of PAI-1 have been reported in preeclamptic mothers. Such an observation is in line with the demonstration that most of the MMP-9 secreted by the preeclamptic trophoblast is in an inactive form, and that antibodies against uPAR are found in pregnant women with a history of fetal loss [69].

Placental ischemia, consequent to poor spiral artery remodeling [87], enhanced Th1/Th2 ratio [93] and pro-angiogenic/anti-angiogenic factor imbalance [94] may promote inflammatory changes through the release of Th-1 cytokines and ROS with consequent endothelial dysfunction, leading to the release of humoral factors responsible for the clinical symptoms of preeclampsia [69].

Several pieces of evidence suggest an involvement of ROS in endothelial alterations of the syndrome [69,83,95,96]. High decidual levels of oxidative stress markers have been found in preeclamptic decidua [95], and some of these are able to inhibit EVT cell invasiveness [96]. Moreover a reduction in glutathione peroxidase has been demonstrated in the preeclamptic placenta, probably correlated with increased *in vitro* placental production of lipid hydroperoxides and thromboxane A₂ (TXA₂), a vasoconstrictive and pro-aggregatory compound, normally counter-regulated by prostacyclin (PGI₂). The consequent TXA₂/PGI₂ imbalance could contribute to the state of high resistance of the utero-placental circulation in preeclampsia. Since NO enhances vasodilatory action of PGI₂ and inhibits TXA₂-mediated-vasoconstriction, its reported decrease in preeclampsia could worsen vascular dysfunction [97]. An enhancement of placental NAD(P)H oxidase activity, possibly stimulated by the increased vascular resistance, has recently been implicated in preeclampsia. Excessive superoxide production could be detrimental, both directly and indirectly, through an increase of cytokine expression [77].

It has been reported that trophoblast cell-derived debris, a by-product of apoptosis in the outer layers of the developing and mature placenta, is present in maternal blood during normal pregnancy. It increases in the blood of preeclamptic women, probably due to an exaggerated apoptosis or even ischaemic necrosis of the oxidatively stressed placenta. This event could represent a further pathogenic mechanism of preeclampsia, through the release of pro-inflammatory cytokines [98].

Therapeutic approaches

In spite of a large amount of research in recent years, the mechanisms underlying physiological pregnancy and their changes which trigger pathological conditions are not completely understood. However, a strong correlation between the features of the inflammatory response and the adverse outcomes of pregnancy has recently been found. Indeed, inflammation is able to subvert the physiological changes that regulate placental perfusion and myometrial tone. Further investigation into the molecules involved in physiological and pathological pregnancy should pave the way to their use, as well as that of their agonists and antagonists, as therapeutic agents. From this perspective, control of the maternal inflammatory response and its influence on vascular and myometrial functions can be accomplished by administration of progesterone and glucocorticoids. Indeed, it has already been established that these hormones influence Th1/Th2 balance in early pregnancy by inhibiting Th1 response, thus favouring anti-inflammatory cytokine production [99,100]. It is also known that, in cases of recurrent pregnancy loss, a Th1 milieu which increases peripheral NK cell number and infiltration of such cells in the endometrium is formed [12,101]. Furthermore, it has recently been demonstrated that glucocorticoids at doses equivalent to those which enhance fetal lung maturity inhibit pro-inflammatory cytokine production in explants from normal and preeclamptic placenta, without altering anti-inflammatory cytokine release [102]. In addition, it has been observed that, at least in mice, progesterone action is exerted through an interaction with glucocorticoid receptors and that corticosterone is 10–100 times more effective than progesterone [99]. However, while progesterone is currently employed as a therapeutic tool during early gestation, the use of glucocorticoids is generally still restricted to the prevention of neonatal respiratory distress syndrome, necrotizing enterocolitis and other severe third trimester complications. The reasons for such a clinical attitude are not clear. They may be due to a deeper concern about the teratogenic effects of glucocorticoids compared with progesterone. Corticosteroid treatment has been found to be ineffective in recurrent pregnancy loss associated with autoantibodies [103]. However it has been reported that low doses of glucocorticoids are not only harmless but even effective in the protection of pregnancy in cases of recurrent abortion of unknown origin [104]. Such efficacy is confirmed daily in our clinical experience. Moreover, recent reports indicate a beneficial effect of preconceptual prednisolone treatment on the outcome of pregnancy in women with history of unexplained recurrent abortion and characterized by elevated levels of NK cells within the endometrium before treatment. In all of these cases, NK cells are reduced upon prednisolone administration [105–107]. Knowing that uNK recruitment is a hormonally-controlled mater-

nal function [10], and that an increased number of these cells is associated with recurrent miscarriage, NK cell cytotoxicity may well represent part of the mechanism by which conceptus rejection takes place. This concept should favour administration of low glucocorticoid doses with a view to preventing sporadic and recurrent abortion, a philosophy currently applied in our clinical practice, which urgently requires extensive investigation. Indeed, it can be speculated that while progesterone is needed in order to prepare the endometrium for the earliest phase of implantation, the subsequent stages of placentation depend on adequate maternal glucocorticoid production, aimed at controlling the factors involved in the inflammatory response which occurs naturally in any tissue remodeling. Based on the above considerations, the administration of glucocorticoids in early pregnancy could be useful to induce the appropriate maternal cytokine environment. Such a role of corticosteroids in securing pregnancy from inflammatory wastage is further enforced by the evidence that mifepristone, a drug employed to induce medical abortion, is a potent antiglucocorticoid [108].

In light of the recent demonstration that some antibiotics, such as ampicillin, reduce amniotic PGE₂ [109,110] and IL-6 release both *in vitro* and *in vivo* [111], by a mechanism independent of their antibacterial properties, their use in the management of the feto-maternal inflammatory state should also be considered. Based on the detrimental role of TXA₂/PGI₂-imbalance in the pathogenesis of preeclampsia, a further therapeutic strategy could be represented by the administration of specific prostanoid blockers, such as piroxicam, a strong inhibitor of thromboxane production in normal and preeclamptic cytotrophoblast [112]. In addition, the clinical benefits of heparin and aspirin in cases of poor pregnancy outcome, such as antiphospholipid syndrome, are also recognized. The use of low doses of these drugs in the management of early pregnancy dysfunction is justified by their influence on EVT differentiation [113] and apoptosis [114]. Finally, considering that inflammation and oxidative stress are features of preeclampsia, a combination of low-dose aspirin and antioxidants like vitamins C and E has been advocated in management of the syndrome, although the possible benefit of such a therapy is still awaiting adequate clinical investigation [95].

Concluding remarks

Advances in recent years have demonstrated that pregnancy outcome depends upon a profound dialogue between the decidua and trophoblast. Such a dialogue is sustained by CT differentiation into ST, as well as EVT, in order to invade maternal spiral arteries for optimal fetal oxygenation and nutrition. A pivotal role in this process has been ascribed to unique uterine wall NK cells, which

are characterized by the ability to produce anti-inflammatory cytokines. It is worth noting that both maternal and paternal factors are responsible for NK cell acquisition of this ability, which appears to depend upon a shift of Th1 towards the Th2 phenotype. Indeed, although a weak inflammatory state is observed during physiological gestation, an exacerbation of this condition is certainly involved in the pathological events leading to pregnancy loss. A delicate balance between free radicals and antioxidants is also essential for normal gestation, since low doses of radicals are thought to be beneficial for both embryo development and pro-inflammatory cytokine control, although their potentiated levels may represent a teratologic threat to fetal tissues and are detrimental for placenta formation. In light of these conclusions, anti-inflammatory and antioxidant therapies are currently evaluated in an attempt to contrast the adverse conditions which lead to pathological pregnancies. Administration of glucocorticoids before conception, or during pregnancy, to prepare and maintain the proper environment for implantation, placentation and fetal growth, appears to represent a new strategy in the battle against pregnancy loss, needing thorough clinical investigation.

Challenges for future research will be to obtain a complete picture of the factors which influence the mechanism of placentation and to identify the very early markers of pathological pregnancies. Progress in this field could allow to design new drugs able to easily reach the feto-maternal unit and suitable for controlling the cytokines involved in the physiological progression of pregnancy.

References

1. Salamonsen LA, Dimitriadis E, Jones RL, Nie G: **Complex regulation of decidualization: a role for cytokines and proteases – a review.** *Placenta* 2003, **24(Suppl A):**76-85.
2. Brosens JJ, Hayashi N, White JO: **Progesterone receptor regulates decidual prolactin expression in differentiating human endometrial stromal cells.** *Endocrinology* 1999, **140:**4809-4820.
3. Brosens JJ, Pijnenborg R, Brosens IA: **The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature.** *Am J Obstet Gynecol* 2002, **187:**1416-1423.
4. Hess AP, Hamilton AE, Talbi S, Dosiou C, Nyegard M, Nayak N, Genbecev-Krtolica O, Mavrogianis P, Ferrer K, Krussel J, Fazleabas AT, Fisher SJ, Giudice LC: **Decidual stromal cell response to paracrine signals from the trophoblast: amplification of immune and angiogenic modulators.** *Biol Reprod* 2006 in press.
5. Oliver C, Montes MJ, Galindo JA, Ruiz C, Olivares EG: **Human decidual stromal cells express alpha-smooth muscle actin and show ultrastructural similarities with myofibroblasts.** *Hum Reprod* 1999, **14:**1599-1605.
6. King A: **Uterine leukocytes and decidualization.** *Hum Reprod Update* 2000, **6:**28-36.
7. Brar AK, Handwerker S, Kessler CA, Aronow BJ: **Gene induction and categorical reprogramming during *in vitro* human endometrial fibroblast decidualization.** *Physiol Genomics* 2001, **7:**135-148.
8. Cooper MA, Fehninger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA: **Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.** *Blood* 2001, **97:**3146-3151.
9. Parham P: **NK cells and trophoblasts: partners in pregnancy.** *J Exp Med* 2004, **200:**951-955.

10. Ordi J, Casals G, Ferrer B, Creus M, Guix C, Palacin A, Campo E, Balasch J: **Uterine (CD56+) natural killer cells recruitment: association with decidual reaction rather than embryo implantation.** *Am J Reprod Immunol* 2006, **55**:369-377.
11. Loke YW, King A: *Human implantation: cell biology and immunology* Cambridge University Press, Cambridge, UK; 1995.
12. Quenby S, Farquharson R: **Uterine natural killer cells, implantation failure and recurrent miscarriage.** *Reprod Biomed Online* 2006, **13**:24-28.
13. Saito S: **Cytokine cross-talk between mother and the embryo/placenta.** *J Reprod Immunol* 2001, **52**:15-33.
14. Saito S, Sakai M: **Th1/Th2 balance in preeclampsia.** *J Reprod Immunol* 2003, **59**:161-173.
15. Khorrani O: **Nitric oxide and its role in blastocyst implantation.** *Rev Endocr Metab Disord* 2002, **3**:145-149.
16. Thathiah A, Brayman M, Dharmaraj N, Julian JJ, Lagow EL, Carson DD: **Tumor necrosis factor alpha stimulates MUC1 synthesis and ectodomain release in a human uterine epithelial cell line.** *Endocrinology* 2004, **145**:4192-4203.
17. Aplin JD, Kimber SJ: **Trophoblast-uterine interactions at implantation.** *Reprod Biol Endocrinol* 2004, **2**:48-59.
18. Hey NA, Aplin JD: **Sialyl-Lewis x and Sialyl-Lewis a are associated with MUC1 in human endometrium.** *Glycoconj J* 1996, **13**:769-779.
19. Meseguer M, Aplin JD, Caballero-Campo P, O'Connor JE, Martin JC, Remohi J, Pellicer A, Simon C: **Human endometrial mucin MUC1 is up-regulated by progesterone and down-regulated in vitro by the human blastocyst.** *Biol Reprod* 2001, **64**:590-601.
20. Spencer TE, Johnson GA, Bazer FW, Burghardt RC: **Implantation mechanisms: insights from the sheep.** *Reproduction* 2004, **128**:657-668.
21. Pijnenborg R: **Implantation and immunology: maternal inflammatory and immune cellular responses to implantation and trophoblast invasion.** *Reprod Biomed Online* 2002, **4**(Suppl 3):14-17.
22. Bokoch GM: **Chemoattractant signaling and leukocyte activation.** *Blood* 1995, **86**:1649-1660.
23. Sargent IL, Borzychowski AM, Redman CW: **NK cells and human pregnancy – an inflammatory view.** *Trends Immunol* 2006, **27**:399-404.
24. Castellucci M, Kosanke G, Verdenelli F, Huppertz B, Kaufmann P: **Vilous sprouting: fundamental mechanisms of human placental development.** *Hum Reprod Update* 2000, **6**:485-494.
25. Loregger T, Pollheimer J, Knöfler M: **Regulatory transcription factors controlling function and differentiation of human trophoblast – a review.** *Placenta* 2003:104-110.
26. Baczyk D, Satkunaratnam A, Nait-Oumesmar B, Huppertz B, Cross JC, Kingdom JC: **Complex patterns of GCM1 mRNA and protein in villous and extravillous trophoblast cells of the human placenta.** *Placenta* 2004, **25**:553-559.
27. Janatpour MJ, Utset MF, Cross JC, Rossant J, Dong J, Israel MA, Fisher SJ: **A repertoire of differentially expressed transcription factors that offers insight into mechanisms of human cytotrophoblast differentiation.** *Dev Genet* 1999, **25**:146-157.
28. Janatpour MJ, McMaster MT, Genbacev O, Zhou Y, Dong J, Cross JC, Israel MA, Fisher SJ: **Id-2 regulates critical aspects of human cytotrophoblast differentiation, invasion and migration.** *Development* 2000, **127**:549-558.
29. Lash GE, Postovit LM, Matthews NE, Chung EY, Canning MT, Pross H, Adams MA, Graham CH: **Oxygen as a regulator of cellular phenotypes in pregnancy and cancer.** *Can J Physiol Pharmacol* 2002, **80**:103-109.
30. Jauniaux E, Gulbis B, Burton GJ: **The human first trimester gestational sac limits rather than facilitates oxygen transfer to the foetus – a review.** *Placenta* 2003, **24**(Suppl A):86-93.
31. Genbacev O, Joslin R, Damsky CH, Polliotti BM, Fisher SJ: **Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia.** *J Clin Invest* 1996, **97**:540-550.
32. Paulding WR, Czyzyk-Krzeska MF: **Hypoxia-induced regulation of mRNA stability.** *Adv Exp Med Biol* 2000, **475**:111-120.
33. Caniggia I, Winter J, Lye SJ, Post M: **Oxygen and placental development during the first trimester: implications for the pathophysiology of pre-eclampsia.** *Placenta* 2000, **21**(Suppl A):25-30.
34. Caniggia I, Grisaru-Gravnosky S, Kuliszewsky M, Post M, Lye SJ: **Inhibition of TGF-beta 3 restores the invasive capability of extravillous trophoblasts in preclampsic pregnancies.** *J Clin Invest* 1999, **103**:1641-1650.
35. Malassine A, Handschuh K, Tsatsaris V, Gerbaud P, Cheynet V, Oriol G, Mallet F, Evain-Brion D: **Expression of HERV-W Env glycoprotein (syncytin) in the extravillous trophoblast of first trimester human placenta.** *Placenta* 2005, **26**:556-562.
36. Dunk C, Shams M, Nijjar S, Rhaman M, Qiu Y, Bussolati B, Ahmed A: **Angiopoietin-1 and angiopoietin-2 activate trophoblast Tie-2 to promote growth and migration during placental development.** *Am J Pathol* 2000, **156**:2185-2199.
37. Bernatchez PN, Soker S, Sirois MG: **Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent.** *J Biol Chem* 1999, **274**:31047-31054.
38. Fong GH, Rossant J, Gertsenstein M, Breitman ML: **Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium.** *Nature* 1995, **376**:66-70.
39. Fukushima K, Miyamoto S, Tsukimori K, Kobayashi H, Seki H, Takeda S, Kensuke E, Ohtani K, Shibuya M, Nakano H: **Tumor necrosis factor and vascular endothelial growth factor induce endothelial integrin repertoires, regulating endovascular differentiation and apoptosis in a human extravillous trophoblast cell line.** *Biol Reprod* 2005, **73**:172-179.
40. Caniggia I, Taylor CV, Ritchie JW, Lye SJ, Letarte M: **Endoglin regulates trophoblast differentiation along the invasive pathway in human placental villous explants.** *Endocrinology* 1997, **138**:4977-4988.
41. Leisser C, Saleh L, Haider S, Husslein H, Sonderegger S, Knöfler M: **Tumor necrosis factor-alpha impairs chorionic gonadotropin beta-subunit expression and cell fusion of human villous cytotrophoblast.** *Mol Hum Reprod* 2006, **12**:601-609.
42. Pollheimer J, Loregger T, Sonderegger S, Saleh L, Bauer S, Bilban M, Czerwenka K, Husslein P, Knöfler M: **Activation of the canonical wingless/T-cell factor signaling pathway promotes invasive differentiation of human trophoblast.** *Am J Pathol* 2006, **168**:1134-1147.
43. LaMarca HL, Morris CA, Pettit GR, Nagowa T, Puschett JB: **Marinobufagenin impairs first trimester cytotrophoblast differentiation.** *Placenta* 2006, **27**:984-988.
44. Crocker IP, Cooper S, Ong SC, Baker PN: **Differences in apoptotic susceptibility of cytotrophoblast and syncytiotrophoblast in normal pregnancy to those complicated with preeclampsia and intrauterine growth restriction.** *Am J Pathol* 2003, **162**:637-643.
45. Kudo Y, Boyd CA, Sargent IL, Redman CW: **Hypoxia alters expression and function of syncytin and its receptor during trophoblast cell fusion of human placental BeWo cells: implications for impaired trophoblast syncytialisation in preeclampsia.** *Biochim Biophys Acta* 2003, **1638**:63-71.
46. Zhou Y, Fisher SJ, Janatpour M, Genbacev O, Dejana E, Wheelock M, Damsky CH: **Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion?** *J Clin Invest* 1997, **99**:2139-2151.
47. Matijevic R, Meekins JW, Walkinshaw SA, Neilson JP, McFadyen IR: **Spiral artery blood flow in the central and peripheral areas of the placental bed in the second trimester.** *Obstet Gynecol* 1995, **86**:289-292.
48. Nanaev AK, Chwalisz K, Frank HG, Kohlen G, Hegele-Hartung C, Kaufmann P: **Physiological dilation of uteroplacental arteries in the guinea pig depends on nitric oxide synthase activity of extravillous trophoblast.** *Cell Tissue Res* 1995, **282**:407-421.
49. Lyall F, Bulmer JN, Kelly H, Duffie E, Robson SC: **Human trophoblast invasion and spiral artery transformation: the role of nitric oxide.** *Am J Pathol* 1999, **154**:1105-1114.
50. Lyall F: **Priming and remodelling of human placental bed spiral arteries during pregnancy – a review.** *Placenta* 2005:31-36.
51. Matthiesen L, Berg G, Ernerudh J, Ekerfelt C, Jonsson Y, Sharma S: **Immunology of preeclampsia.** *Chem Immunol Allergy* 2005, **89**:49-61.
52. Moffet-King A: **Natural killer cells and pregnancy.** *Nature Review Immunology* 2002, **2**:656-663.
53. Lyall F, Bulmer JN, Duffie E, Cousins F, Theriault A, Robson SC: **Human trophoblast invasion and spiral artery transformation: the role of PECAM-1 in normal pregnancy, preeclampsia**

- sia, and fetal growth restriction. *Am J Pathol* 2001, **158**:1713-1721.
54. Kilburn BA, Wang J, Duniec-Dmuchowski ZM, Leach RE, Romero R, Armant DA: **Extracellular matrix composition and hypoxia regulate the expression of HLA-G and integrins in a human trophoblast cell line.** *Biol Reprod* 2000, **62**:739-747.
 55. Graham CH, Fitzpatrick TE, McCrae KR: **Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway.** *Blood* 1998, **91**:3300-3307.
 56. Bukovsky A, Caudle MR, Cekanova M, Fernando RI, Wimalasena J, Foster JS, Henley DC, Elder RF: **Placental expression of estrogen receptor beta and its hormone binding variant-comparison with estrogen receptor alpha and a role for estrogen receptors in asymmetric division and differentiation of estrogen-dependent cells.** *Reprod Biol Endocrinol* 2003, **1**:36-57.
 57. Nicola C, Timoshenko AV, Dixon SJ, Lala PK, Chakraborty C: **EPI receptor-mediated migration of the first trimester human extravillous trophoblast: the role of intracellular calcium and calpain.** *J Clin Endocrinol Metab* 2005, **90**:4736-4746.
 58. Biondi C, Ferretti ME, Pavan B, Lunghi L, Gravina B, Nicoloso MS, Vesce F, Baldassarre G: **Prostaglandin E₂ inhibits proliferation and migration of HTR-8/SVneo cells, a human trophoblast-derived cell line.** *Placenta* 2006, **27**:592-601.
 59. Hamilton GS, Lysiak JJ, Watson A, Lala PK: **Effects of colony stimulating factor-1 on human extravillous trophoblast growth and invasion.** *J Endocrinol* 1998, **159**:69-77.
 60. Xu G, Guimond MG, Chakraborty C, Lala PK: **Control of proliferation, migration, and invasiveness of human extravillous trophoblast by decorin, a decidual product.** *Biol Reprod* 2002, **67**:681-689.
 61. Lysiak JJ, Connelly I, Khoo N, Stetler-Stevenson W, Lala PK: **Role of transforming growth factor-beta and epidermal growth factor (EGF) on proliferation and invasion by first trimester human trophoblast.** *Trophoblast Res* 1994, **8**:455-467.
 62. Chakraborty C, Barbin YP, Chakrabarti S, Dixon SJ, Lala PK: **Role of endothelin (ET)-1 in the functional regulation of human extravillous (EVT) cells.** *Placenta* 2001, **22**:A22.
 63. Cartwright JE, Holden DP, Whitley GS: **Hepatocyte growth factor regulates human trophoblast motility and invasion: a role for nitric oxide.** *Br J Pharmacol* 1999, **128**:181-189.
 64. Irving JA, Lala PK: **Functional role of cell surface integrins on human trophoblast cell migration regulation by TGF-beta, IGF-II and IGFBP-1.** *Exp Cell Res* 1995, **217**:419-27.
 65. Hamilton G, Lysiak J, Han V, Lala PK: **Autocrine-paracrine regulation of human trophoblast invasiveness by insulin-like growth factor (IGF)-II and IGF binding protein (IGFBP)-1.** *Exp Res Cell* 1998, **244**:147-156.
 66. Shih I, Wang T, Wu T, Kurman R, Gearhart J: **Expression of Mel-CAM in implantation site intermediate trophoblastic cell line, IST-1, limits its migration on uterine smooth muscle cells.** *J Cell Sci* 1998, **111**:2655-2664.
 67. Bauer S, Pollheimer J, Hartmann J, Husslein P, Aplin JD, Knofler M: **Tumor necrosis factor- α inhibits trophoblast migration through elevation of plasminogen activator inhibitor-1 in first-trimester villous explant cultures.** *J Clin Endocrinol Metab* 2004, **89**:2812-2822.
 68. Munir S, Xu G, Wu Y, Yang B, Lala PK, Peng C: **Nodal and activin receptor-like kinase (ALK) 7 inhibit proliferation and induce apoptosis in human trophoblast cells.** *J Biol Chem* 2004, **279**:31277-31286.
 69. Lala PK, Chakraborty C: **Factors regulating trophoblast migration and invasiveness: possible derangements contributing to pre-eclampsia and fetal injury.** *Placenta* 2003, **24**:575-587.
 70. Staff AC, Ranheim T, Henriksen T, Halvorsen B: **8-iso-Prostaglandin F_{2 α} reduces trophoblast invasion and matrix metalloproteinase activity.** *Hypertension* 2000, **35**:1307-1313.
 71. Athanassiades A, Lala PK: **Role of placenta growth factor (PGF) in human extravillous trophoblast proliferation, migration and invasiveness.** *Placenta* 1998, **19**:465-473.
 72. Bauer S, Pollheimer J, Hartmann J, Husslein P, Aplin JD, Knofler M: **Tumor necrosis factor-alpha inhibits trophoblast migration through elevation of plasminogen activator inhibitor-1 in first-trimester villous explant cultures.** *J Clin Endocrinol Metab* 2004, **89**:812-822.
 73. Athanassiades A, Hamilton G, Lala PK: **Vascular endothelial growth factor stimulates proliferation but not migration or invasiveness in human extravillous trophoblast.** *Biol Reprod* 1998, **59**:643-654.
 74. Ramirez-Bergeron DL, Runge A, Dahl KD, Fehling HJ, Keller G, Simon MC: **Hypoxia affects mesoderm and enhances hemangioblast specification during early development.** *Development* 2004, **131**:4623-4634.
 75. Guerin P, El Mouatassim S, Menezo Y: **Oxidative stress and protection against reactive oxygen species in the pre-implantation embryo and its surroundings.** *Hum Reprod Update* 2001, **7**:175-189.
 76. McAleer MF, Tuan RS: **Cytotoxicant-induced trophoblast dysfunction and abnormal pregnancy outcomes: role of zinc and metallothionein.** *Birth Defects Res C Embryo Today* 2004, **72**:361-370.
 77. Myatt L, Cui X: **Oxidative stress in the placenta.** *Histochem Cell Biol* 2004, **122**:369-382.
 78. Raijmakers MT, Burton GJ, Jauniaux E, Seed PT, Peters WHM, Steegers EAP, Poston L: **Placental NAD(P)H oxidase mediated superoxide generation in early pregnancy.** *Placenta* 2006, **27**:158-163.
 79. Allen RG, Balin AK: **Oxidative influence on development and differentiation: an overview of a free radical theory of development.** *Free Rad Biol Med* 1989, **6**:631-661.
 80. Droge W: **Free radicals in the physiological control of cell function.** *Physiol Rev* 2002, **82**:47-95.
 81. Goto Y, Noda Y, Mori T, Nakano M: **Increased generation of reactive oxygen species in embryos cultured in vitro.** *Free Radic Biol Med* 1993, **15**:69-75.
 82. Ohyama K, Yuan B, Bessho T, Yamakawa T: **Progressive apoptosis in chorion laeve trophoblast cells of human fetal membrane tissues during in vitro incubation is suppressed by antioxidant reagents.** *Eur J Biochem* 2001, **268**:6182-6189.
 83. Biondi C, Pavan B, Lunghi L, Fiorini S, Vesce F: **The role and modulation of the oxidative balance in pregnancy.** *Curr Pharm Des* 2005, **11**:2075-2089.
 84. Bromage SJ, Lang AK, Atkinson I, Searle RF: **Abnormal TGFbeta levels in the amniotic fluid of Down syndrome pregnancies.** *Am J Reprod Immunol* 2000, **44**:205-210.
 85. Vesce F, Scapoli C, Giovannini G, Tralli L, Gotti G, Valerio A, Piffanelli A: **Cytokine imbalance in pregnancies with fetal chromosomal abnormalities.** *Hum Reprod* 2002, **17**:803-808.
 86. Wright A, Zhou Y, Weier JF, Caceres E, Kapidzic M, Tabata T, Kahn M, Nash C, Fisher SJ: **Trisomy 21 is associated with variable defects in cytotrophoblast differentiation along the invasive pathway.** *Am J Med Genet* 2004, **130**:354-364.
 87. Kharfi A, Giguère Y, Sapin V, Massé J, Dastugue B, Forest JC: **Trophoblastic remodeling in normal and preeclamptic pregnancies: implication of cytokines.** *Clin Biochem* 2003, **36**:323-331.
 88. Hiby SE, Walker JJ, O'Shaughnessy KM, Redman CWG, Carrington M, Trowsdale J, Moffett A: **Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success.** *J Exp Med* 2004, **200**:957-965.
 89. Allaire AD, Ballenger KA, Wells SR, McMahon MJ, Lessey BA: **Placental apoptosis in preeclampsia.** *Obstet Gynecol* 2000, **96**:271-276.
 90. Zhou Y, Damsky CH, Fisher SJ: **Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?** *J Clin Invest* 1997, **99**:2152-2164.
 91. Redline RW, Patterson P: **Pre-eclampsia is associated with an excess of proliferative immature intermediate trophoblast.** *Hum Pathol* 1995, **26**:594-600.
 92. Hamai Y, Fujii T, Yamashita T, Miki A, Hyodo H, Kozuma S, Geraghty DE, Taketani Y: **The expression of human leukocyte antigen-G on trophoblasts abolishes the growth-suppressing effect of interleukin-2 towards them.** *Am J Reprod Immunol* 1999, **41**:153-158.
 93. Yoneyama Y, Suzuki S, Sawa R, Yoneyama K, Power GG, Araki T: **Relation between adenosine and T-helper 1/T-helper 2 imbalance in women with preeclampsia.** *Obstet Gynaecol* 2002, **99**:641-646.
 94. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y: **Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia.** *J Clin Endocrinol Metab* 2003, **88**:2348-2351.

95. Raijmakers MT, Dechend R, Poston L: **Oxidative stress and preeclampsia: rationale for antioxidant clinical trials.** *Hypertension* 2004, **44**:374-380.
96. Tjoa ML, Oudejans CBM, van Vugt JMG, Blankenstein MA, van Wijk IJ: **Markers for presymptomatic prediction of preeclampsia and intrauterine growth restriction.** *Hypertens Pregnancy* 2004, **23**:171-189.
97. Lyall F, Young A, Greer IA: **Nitric oxide concentrations are increased in the fetoplacental circulation in preeclampsia.** *Am J Obstet Gynecol* 1995, **173**:714-718.
98. Robertson SA, Redman CW, McCracken SA, Hunt JS, Dimitriadis E, Moffet-King A, Chamley L: **Immune modulators of implantation and placental development – a workshop report.** *Placenta* 2003, **24(Suppl A)**:16-20.
99. Miyaura H, Iwata M: **Direct and indirect inhibition of Th1 development by progesterone and glucocorticoids.** *J Immunol* 2002, **168**:1087-1094.
100. Kozma N, Halasz M, Palkovics T, Szekeres-Bartho J: **The progesterone-induced blocking factor modulates the balance of PKC and intracellular Ca.** *Am J Reprod Immunol* 2006, **55**:122-129.
101. Dosiou C, Giudice LC: **Natural killer cells in pregnancy and recurrent pregnancy loss: endocrine and immunologic perspectives.** *Endocrine Rev* 2005, **26**:44-62.
102. Xu G, Makris A, Thornton C, Hennessy A: **Glucocorticoids inhibit placental cytokines from cultured normal and preeclamptic placental explants.** *Placenta* 2005, **26**:654-660.
103. Laskin CA, Bombardier C, Hannah ME, Mandel FP, Ritchie JW, Farewell V, Farine D, Spitzer K, Fielding L, Soloninka CA, Yeung M: **Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss.** *N Engl J Med* 1997, **337**:148-153.
104. Sidhu RK: **Corticosteroids in pregnancy.** In *Drugs and pregnancy. Human teratogenesis and related problems* 2nd edition. Edited by: Hawkins DF. Churchill Livingstone: Edinburgh London Melbourne and New York; 1987:167-179.
105. Redman CW, Sargent IL: **Latest advances in understanding preeclampsia.** *Science* 2005, **308**:1592-1594.
106. Quenby S, Kalumbi C, Bates M, Farquharson R, Vince G: **Prednisolone reduces preconceptual endometrial natural killer cells in women with recurrent miscarriage.** *Fertil Steril* 2005, **84**:980-984.
107. Ogasawara M, Aoki K: **Successful uterine steroid therapy in a case with a history of ten miscarriages.** *Am J Reprod Immunol* 2000, **44**:253-255.
108. Heikinheimo O, Raivio T, Honkanen H, Ranta S, Janne OA: **Termination of pregnancy with mifepristone and prostaglandin suppresses transiently circulating glucocorticoid bioactivity.** *J Clin Endocrinol Metab* 2003, **88**:323-326.
109. Vesce F, Buzzi M, Ferretti ME, Pavan B, Bianciotto A, Jorizzo G, Biondi C: **Inhibition of amniotic prostaglandin E release by ampicillin.** *Am J Obstet Gynecol* 1998, **178**:759-764.
110. Vesce F, Pavan B, Buzzi M, Pareschi MC, Bianciotto A, Jorizzo G, Biondi C: **Effect of different classes of antibiotics on amniotic prostaglandin E release.** *Prostaglandins Other Lipid Mediat* 1999, **57**:207-218.
111. Vesce F, Pavan B, Lunghi L, Giovannini G, Scapoli C, Piffanelli A, Biondi C: **Inhibition of amniotic interleukin-6 and prostaglandin E2 release by ampicillin.** *Obstet Gynecol* 2004, **103**:108-113.
112. Ding ZQ, Rowe J, Ng B, Sinovich MJ, Gallery ED: **Modulation of prostacyclin and thromboxane secretion by cytotrophoblasts from normal and pre-eclamptic human pregnancies.** *Placenta* 2002, **23**:594-599.
113. Quenby S, Mountfield S, Cartwright JE, Whitley GS, Vince G: **Effects of low-molecular-weight and unfractionated heparin on trophoblast function.** *Obstet Gynecol* 2004, **104**:354-361.
114. Bose P, Black S, Kadyrov M, Weissborn U, Neulen J, Regan L, Hupertz B: **Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure.** *Am J Obstet Gynecol* 2005, **192**:23-30.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

